ArticleInternational journal of environmental research and public health2022

Modified-Dose Pembrolizumab and Prognostic Outcomes among Non-Small Cell Lung Cancer Patients: A Chart Review Study.

Sheng-Yin To et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.